secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2022-05-27T23:59:59+00:00
Accession:  0001564590-22-021452
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes appoints Dr. Wright to board; two directors retire; new lead independent director
--------------------------------------------------------------------------------

- Christopher I. Wright, M.D., Ph.D., appointed to board effective May 24, 2022, bringing neuroscience expertise.
- David W. Anstice and Wendy L. Dixon will retire at the 2022 annual meeting; Nancy J. Wysenski named new Lead Independent Director.
- Board added seven independent directors since 2019; average tenure dropped from ~6 to ~3 years.
- Company engaged with Sarissa Capital in over 20 meetings; declined Sarissa's nominees but appointed Wright after collaboration attempts.
- Filing of preliminary proxy statement for 2022 annual meeting; board declassification and plurality voting standard approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000156459022021452/0001564590-22-021452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000156459022021452/alks-8k_20220524.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-021452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer